We recently compiled a list of the 10 Best Guru Stocks To Buy Now. In this article, we will have a look at where Roivant ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

Roivant (ROIV) announces Pulmovant, a new Vant member to develop lung disorder therapy mosliciguat, in licensed from Bayer ...

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...

The deal hands Organon a psoriasis and eczema cream called Vtama, while Roivant will get more cash to fund its R&D plans.

Roivant executives believe that mosliciguat, administered once per day using a dry powder inhaler, will help fill "an unmet ...

Goldman Sachs analyst Chris Shibutani has maintained their bullish stance on ROIV stock, giving a Buy rating today. Chris Shibutani has given ...

Shares of Roivant Sciences stock opened at $11.92 on Friday. Roivant Sciences Ltd. has a 12-month low of $8.24 and a 12-month high of $13.24. The stock has a market cap of $8.81 billion ...

On Wednesday, Roivant Sciences (NASDAQ:ROIV) shares maintained a Buy rating from TD Cowen, following the announcement of a significant licensing agreement with Organon. The deal, which involves ...

Shares of Roivant, which owns 86% of Dermavant as of March 31, 2024, and was founded by former Republican presidential candidate Vivek Ramaswamy, were up 1.7% at $12.26 in early trading.